Actavis Loss In ADHD Drug IP Fight Backed By Fed. Circ.

By Adam Lidgett (July 7, 2022, 4:04 PM EDT) -- The Federal Circuit has upheld a ruling from Delaware's top federal judge that found a Teva unit failed to show three patents on the ADHD treatment Quillivant XR were invalid, finding the unit had not proved the judge made any errors....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!